The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

J&J ’s JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the ...

Nipocalimab has shown to be more effective than current treatment methods in preventing and managing HDFN. Johnson & Johnson’s nipocalimab, an investigational therapy currently being studied in ...

Earlier this year, nipocalimab data from Vivacity-MG3 supported the medication's long-term use in generalized myasthenia gravis when it is added to standard-of-care therapies. In particular ...

The American Academy of Neurology (AAN) Annual Meeting 2025 took place in San Diego, California on April 5-9, 2025. This prestigious gathering served as a pivotal platform for neurological ...